Sugi Predict

Sugi Predict / Compounds / SCHEMBL29604975

SCHEMBL29604975

SCHEMBL29604975

CC1=CCCC(C)(C)C1/C=C/C(C)=C/C=C\C(C)=C\C=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.56
▸ CYP3A4 P08684 5/20 0.56
▸ ALOX15 P16050 4/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ TRPV1 Q8NER1 1/20 0.50
▸ KDM4E B2RXH2 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ TSHR P16473 2/20 0.44
▸ APP P05067 2/20 0.44
▸ SNCA P37840 2/20 0.44
▸ TP53 P04637 1/20 0.44
▸ NR2E1 Q9Y466 1/20 0.44
▸ MAPT P10636 8/20 0.35
▸ PTGS1 P23219 4/20 0.34
▸ LMNA P02545 3/20 0.34
▸ DRD3 P35462 2/20 0.34
▸ SLCO1B3 Q9NPD5 1/20 0.34
▸ SLCO1B1 Q9Y6L6 1/20 0.34
▸ HIF1A Q16665 3/20 0.34
▸ GMNN O75496 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14566202 1.00 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1TRPV1
SCHEMBL14566281 1.00 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1TRPV1
SCHEMBL29435876 0.92 ALDH1A1 (0.58) ALDH1A1CYP3A4ALOX15TDP1TRPV1
SCHEMBL13580513 0.91 ALDH1A1 (0.55) ALDH1A1CYP3A4ALOX15TDP1TRPV1
SCHEMBL5532432 0.86 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL9856621 0.86 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL12494830 0.86 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL15609523 0.86 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL12494087 0.86 ALDH1A1 (0.56) ALDH1A1CYP3A4ALOX15TDP1KDM4E
SCHEMBL4285043 0.85 ALDH1A1 (0.52) ALDH1A1CYP3A4ALOX15TDP1TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026107299-A1 ENGINEERED VIRAL CAPSIDS FOR THERAPEUTIC DELIVERY Avirmax Biopharma Inc. (US) 2026-05-21 — — WO disclosed
WO-2026106270-A1 AAV-BASED PDE6B VIRAL VECTOR FOR TREATING RETINITIS PIGMENTOSA CONTAINING TISSUE-SPECIFICALLY EXPRESSED PDE6A PROMOTER, AND USE THEREOF (주) 씨드모젠 2026-05-21 — — WO disclosed
US-12624347-B2 Wireless activation of channelrhodopsin via in situ self-assembly of semiconductor quantum dots at the plasma membrane THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 2026-05-12 — — US disclosed
US-12282027-B2 High-throughput NMR approach for in-membrane protein ligand screening UNIVERSITY OF SOUTH FLORIDA (US) 2025-04-22 — — US disclosed
EP-4511075-A1 GELMA POLYMER COMPOSITIONS COMPRISING CELLS Gelmedix, Inc. (US) 2025-02-26 — — EP disclosed
CN-105593240-B Method for determining mutable ligand-GPCR binding with single amino acid resolution, and mutant ligand and GPCR pairs 保罗·谢勒学院 2024-05-31 — — CN disclosed
US-20230399622-A1 THERAPY FOR DEGENERATIVE DISEASE AND TISSUE DAMAGE FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) 2023-12-14 — — US disclosed
WO-2023205265-A1 GELMA POLYMER COMPOSITIONS COMPRISING CELLS GELMEDIX, INC. (US) 2023-10-26 — — WO disclosed
EP-4243848-A2 ENGINEERED VIRAL CAPSIDS AND METHODS OF USE Avirmax Biopharma Inc. (US) 2023-09-20 — — EP disclosed
CN-116648265-A Composition for treating or preventing diseases, disorders or symptoms associated with endoplasmic reticulum stress or all-trans retinal, or for protecting retinal thickness, or for inhibiting atrophy or progression of atrophy of retinal thickness 锐视维公司 2023-08-25 — — CN disclosed
WO-2023039480-A2 ENGINEERED CENTRAL NERVOUS SYSTEM COMPOSITIONS THE BROAD INSTITUTE, INC. (US) 2023-03-16 — — WO disclosed
EP-4110316-A1 COMPOSITIONS AND METHODS FOR TREATING MISFOLDED PROTEIN OCULAR DISORDERS CASE WESTERN RESERVE UNIVERSITY (US) 2023-01-04 — — EP disclosed
CN-115552018-A Treatment of autosomal recessive BESTROPHIN disease and method for evaluating the same 宾夕法尼亚州大学信托人 2022-12-30 — — CN disclosed
CN-115252823-A Gene therapy for retinitis pigmentosa 建新公司 2022-11-01 — — CN disclosed
CN-115243766-A Treatment of autosomal dominant bestrol disease and methods for evaluating the same 宾夕法尼亚州大学信托人 2022-10-25 — — CN disclosed
US-20220283178-A1 HIGH-THROUGHPUT NMR APPROACH FOR IN-MEMBRANE PROTEIN LIGAND SCREENING UNIVERSITY OF SOUTH FLORIDA 2022-09-08 — — US disclosed
CN-109970708-B Cannabinoid receptor modulators 艾尼纳制药公司 2022-06-21 — — CN disclosed
CN-106456660-B Gene therapy for retinitis pigmentosa 建新公司 2022-05-31 — — CN disclosed
WO-2022103766-A2 ENGINEERED VIRAL CAPSIDS AND METHODS OF USE AVIRMAX, INC. (US) 2022-05-19 — — WO disclosed
WO-2022079322-A1 THERAPY FOR DEGENERATIVE DISEASE AND TISSUE DAMAGE FUNDACIÓ CENTRE DE REGULACIÓ GENÒMICA (ES) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12624347-B2 Wireless activation of channelrhodopsin via in situ self-assembly of semiconductor quantum dots at the plasma membrane TRPC1, TRPC6, CRY2 ALDH1A1 4580/4885CYP3A4 4229/4885ALOX15 4866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback